LinkedIn·Wednesday, 19 August 2026·7d ago
Barcelona, 7 to 9 September. We will be at Advanced Therapies Europe, where regulatory planning, manufacturing and market access all sit on…
Antleron
3,005 followers
Barcelona, 7 to 9 September. We will be at Advanced Therapies Europe, where regulatory planning, manufacturing and market access all sit on one programme.
Our mission at Antleron is to get cell and gene therapies to more patients, faster and more affordably. We work at the point where digital innovation meets GMP reality, combining scaled-down models and closed, automated manufacturing with hybrid digital twins that pair mechanistic understanding with machine learning. The aim is CMC robustness and process economics that still hold at scale.
Jan Schrooten, our CEO, is keen to talk about what it takes for digital process
development to hold up in real manufacturing and in front of a regulator, instead of staying a promising lab result.
See you in Barcelona? Reach out and let's make time to talk.
📍 InterContinental, Barcelona
📅 7-9 September 2026
#ATE26 #bioprocess #cgt #atmp #biomanufacturing #cmc
♥ 53↻ 2
View on LinkedIn Cross-referenced
Related on the wire
𝗗𝗼 𝘄𝗲 𝗹𝗼𝘀𝗲 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝗼𝗳 𝗼𝘂𝗿 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗻𝗰𝗲 𝗔𝗻𝘁𝗹𝗲𝗿𝗼𝗻 𝗯𝘂𝗶𝗹𝗱𝘀 𝘁𝗵𝗲…
𝗕𝗮𝘁𝗰𝗵-𝘁𝗼-𝗯𝗮𝘁𝗰𝗵 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝘀 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝘀𝘁𝘂𝗯𝗯𝗼𝗿𝗻 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 𝗶𝗻 𝗖𝗚𝗧…
𝗪𝗵𝗮𝘁 𝗶𝗳 𝘆𝗼𝘂𝗿 𝗳𝗶𝘅𝗲𝗱-𝗯𝗲𝗱 𝗯𝗶𝗼𝗿𝗲𝗮𝗰𝘁𝗼𝗿 𝗰𝗼𝘂𝗹𝗱 𝘁𝗲𝗹𝗹 𝘆𝗼𝘂 𝗵𝗼𝘄 𝗺𝗮𝗻𝘆 𝗰𝗲𝗹𝗹𝘀 𝗮𝗿𝗲 𝗶𝗻𝘀𝗶𝗱𝗲? In…
Process development always involves trade-offs. Push for higher yield and your cost creeps up. Optimize for cost and you risk falling short…
Evan Claes is teaching a three-hour short course on Analytical Quality-by-Design for ATMPs at today's DA-PBA symposium. Robust, real-time…
In CGT process development, the questions change as you go. Early on you want to understand and explore your process. Further along you…